Dogwood Therapeutics (NASDAQ:DWTX) Announces Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02, FiscalAI reports. The firm had revenue of $0.10 million for the quarter.

Dogwood Therapeutics Trading Up 23.1%

DWTX traded up $0.24 on Friday, reaching $1.28. The company had a trading volume of 171,530 shares, compared to its average volume of 78,791. The company has a fifty day moving average of $1.56 and a 200-day moving average of $1.96. The company has a market capitalization of $48.93 million, a P/E ratio of -0.14 and a beta of 2.08. Dogwood Therapeutics has a one year low of $0.90 and a one year high of $7.04.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Thursday, October 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.